Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16605543 | 0.84 | S1PR1 (0.49) | S1PR1S1PR3MAPTRAB9A | |
| SCHEMBL24891909 | 0.79 | S1PR1 (0.55) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24892340 | 0.79 | S1PR1 (0.68) | S1PR1S1PR3PLAU | |
| SCHEMBL16605300 | 0.77 | GRM4 (0.48) | S1PR1GRM4 | |
| SCHEMBL24891915 | 0.73 | KCNH2 (0.47) | S1PR1S1PR3KMONPC1RAB9A | |
| SCHEMBL24892341 | 0.70 | S1PR1 (0.65) | S1PR1S1PR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16605492 | 0.70 | TMPRSS4 (0.40) | — | |
| SCHEMBL24891901 | 0.69 | MMP13 (0.54) | S1PR1S1PR3MMP13PLAU | |
| SCHEMBL5575474 | 0.68 | S1PR1 (0.38) | S1PR1KMONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3226691 | 0.68 | RAB9A (0.51) | MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | PC, CPS1, GLS2 | S1PR1 1131/4885S1PR3 1179/4885MAPT 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.